Efficacy of TNFα inhibitors for refractory vascular Behçet's disease: A multicenter observational study of 27 patients and a review of the literature.
Aysun AksoyAyten YazıcıAhmet OmmaAyse CefleFatos OnenUnal TasdemirTulin ErgunRafi Haner DireskeneliFatma Alibaz-OnerPublished in: International journal of rheumatic diseases (2020)
Tumor necrosis factor-alpha inhibitors seem a highly effective option for remission-induction of refractory VBD with an acceptable safety data. Concomitant IS use may achieve higher complete remission rates as compared to TNFα inhibitor monotherapy. Comparative efficacy and safety of biological agents for VBD require further prospective, randomized controlled studies with a longer duration of follow-up.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- disease activity
- open label
- double blind
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- clinical trial
- big data
- randomized controlled trial
- electronic health record
- cross sectional
- phase iii
- combination therapy
- phase ii
- patient reported outcomes
- deep learning
- artificial intelligence
- patient reported